Facebook
Twitter
LinkedIn
Forward
Glaucoma Debate Club 2022: Cases in Sustained IOP Control (Archived CME Monograph)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
The successful treatment of glaucoma is challenged by many factors, including patient nonadherence to topical therapies, waning efficacy of topical therapies as disease progresses, and risks associated with traditional glaucoma surgery. As a result, several new approaches for managing glaucoma have been introduced that can help address some of the challenges posed by traditional medical therapy. These include sustained drug-eluting devices and minimally invasive surgical procedures. The choice of intervention is not straightforward, and a nuanced, patient-centered approach to selection is needed. In this educational activity, experts explore different treatment options for various patient scenarios through cases in a debate-style format. The desired result of this educational activity is to enable glaucoma specialists and other ophthalmologists to confidently incorporate a variety of new treatments beyond topical drugs to improve visual outcomes for patients with glaucoma.
Target Audience
This educational activity is intended for glaucoma specialists and other ophthalmologists caring for patients with glaucoma.
Learning Objectives
After completing this activity, participants will be better able to:
- Review safety and efficacy data for approved and emerging sustained-release drug delivery devices for glaucoma
- Identify patients with glaucoma who are most likely to benefit from sustained-release drug delivery treatment
- Choose appropriate MIGS procedures for a variety of patient scenarios
Faculty
 | Iqbal Ike K. Ahmed, MD, FRCSC (Co-Chair) Professor Department of Ophthalmology and Visual Sciences University of Utah Salt Lake City, Utah Director, Alan S. Crandall Center for Glaucoma Innovation John A. Moran Eye Center Director, Glaucoma & Advanced Anterior Segment Surgery (GAASS) Fellowship Research Director, Kensington Eye Institute University of Toronto Toronto, Canada Division Head, Ophthalmology Trillium Health Partners Mississauga, Canada Chief Innovation Officer Prism Eye Institute Oakville, Canada |
 | Thomas W. Samuelson, MD (Co-Chair) Founding Partner and Attending Surgeon Glaucoma and Anterior Segment Surgery Minnesota Eye Consultants Adjunct Professor University of Minnesota Minneapolis, Minnesota |
 | Marlene R. Moster, MD Professor of Ophthalmology Thomas Jefferson University School of Medicine Attending Surgeon, Glaucoma Service Wills Eye Institute Philadelphia, Pennsylvania |
 | Arsham Sheybani, MD Assistant Professor of Ophthalmology Fellowship Director, Glaucoma and Anterior Segment Surgery Residency Program Director, Ophthalmology Washington University School of Medicine St Louis, Missouri |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Iqbal Ike K. Ahmed, MD, is a consultant for Aequus BioPharma, Inc, Aerie Pharmaceuticals, Inc, Akorn, Inc, Alcon, Allergan, Aquea Health, Inc, ArcScan, Inc, Avisi, Bausch & Lomb Incorporated, Beaver-Visitec International, Beyeonics Surgical Ltd, Bionode, Carl Zeiss Meditec, Inc, CorNeat Vision Ltd, Elios Vision, ElutiMed, Equinox, Genentech, Inc, Glaukos Corporation, Heine, Heru, Iantrek, iCare, Injectsense, Inc, IRIDEX Corporation, iSTAR, Ivantis Inc, Johnson & Johnson Vision Care, Inc, LayerBio, Inc, MicroOptx, MicroSurgical Technology, Myra Vision, New World Medical, Inc, Ocular Instruments, Ocular Therapeutix, Inc, Omega Ophthalmics, Polyactiva Pty Ltd, Radiance Therapeutics, Inc, Ripple Therapeutics, Sanoculis Ltd, Santen Inc, Shifamed, LLC, Sight Sciences, Smartlens, Inc, Strõma Medical Corporation, Thea Pharmaceuticals Limited, Vialase, Inc, Vizzario, and W. L. Gore & Associates, Inc; is on the speakers bureau for Alcon, Allergan, Carl Zeiss Meditec, Inc, Heine, Johnson & Johnson Vision Care, Inc, and MicroSurgical Technology; and is a contracted researcher for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bionode, Glaukos Corporation, iCare, Ivantis Inc, Johnson & Johnson Vision Care, Inc, New World Medical, Inc, and Santen Inc.
Marlene R. Moster, MD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, and Qura; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Alcon, Allergan, and Bausch & Lomb Incorporated; is a contracted researcher for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Glaukos Corporation, InnFocus, Inc, and New World Medical, Inc; and has individual stocks or stock options in Qura.
Thomas W. Samuelson, MD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Belkin Vision, ELT Sight, Equinox, Glaukos Corporation, Imprimis Pharmaceuticals, Inc, Ivantis Inc, Johnson & Johnson Vision Care, Inc, MicroOptx, New World Medical, Inc, Ocuphire Pharma, Polyactiva Pty Ltd, Ripple Therapeutics, Santen Inc, Sight Sciences, TearClear, Valeant, ViaLase, Inc, and Zeiss; and has individual stocks or stock options in Belkin Vision, Equinox, Ivantis Inc, Ocuphire Pharma, Sight Sciences, TearClear, and ViaLase, Inc.
Arsham Sheybani, MD, is a consultant for AbbVie Inc, Alcon, Glaukos Corporation, Ivantis Inc, and Santen Inc.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Tony Realini, MD, is a consultant for Belkin Laser, iStar Medical, Ivantis Inc, New World Medical, Inc, Ocular Therapeutix, Inc, Oyster Point Pharma Inc, and Sight Sciences.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from AbbVie Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or AbbVie Inc.
©2022 MedEdicus LLC. 265.2